Based on data demonstrating a difference in the dependence of CAFs on BCL-2 vs. MCL-1 for survival, studies have shown that CAFs in human breast cancer are sensitive to inhibitors targeting MCL-1 (A-1210477 and S63845) but not to those targeting BCL-2/BCL-XL (ABT-737 and navitoclax) [91]. Here, MCL1 is linked to breast cancer.